載入中
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
一般交易時段
US$15.751
−US$1.379 · -8.05%
盤中時間採用ET。市場資料可能有所延遲。
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$15.751
52週區間
目前US$15.751
盤中時間採用ET。市場資料可能有所延遲。
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$15.751
52週區間
目前US$15.751
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 58.32萬 USD | 133.77萬 USD |
| 毛利 | — | — | — | 58.32萬 USD | 133.77萬 USD |
| 研究與開發 | 5.38億 USD | 1.32億 USD | 4.55億 USD | 4301.46萬 USD | 6311.52萬 USD |
| 銷售、一般及管理費用 | 5.57億 USD | 4834.53萬 USD | 2374.08萬 USD | 2212.23萬 USD | 1745.96萬 USD |
| 營業費用 | 10.94億 USD | 1.81億 USD | 4.78億 USD | 6021.67萬 USD | 6506.97萬 USD |
| 利息收入 | 1550.1萬 USD | 1346.6萬 USD | 1040.3萬 USD | 151.3萬 USD | — |
| 利息支出 | — | 868.6萬 USD | 1646.1萬 USD | 440.1萬 USD | 20.83萬 USD |
| 折舊和攤銷 | 14.6萬 USD | 8.9萬 USD | 19.8萬 USD | 126.3萬 USD | 245.5萬 USD |
| 營業利益 | −10.94億 USD | −1.81億 USD | −4.78億 USD | −5963.35萬 USD | −6373.2萬 USD |
| 淨利 | −10.8億 USD | −1.77億 USD | −4.82億 USD | −6517萬 USD | −6551.85萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$29.33
上漲空間 86.21%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI6494.4萬0.63%103.03億 USD0.35%US$147.64-2.48%
Vanguard Morningstar Total Stock Market ETFVTI5060.97萬0.00%2.3兆 USD0.03%US$381.25-0.08%
Vanguard Morningstar Small-Cap ETFVB3646.74萬0.02%1853億 USD0.03%US$288.4+0.08%
Vanguard Extended Market ETFVXF2459.88萬0.03%954億 USD0.05%US$232.8-0.31%
Vanguard Morningstar Small-Cap Value ETFVBR2317.06萬0.03%682億 USD0.05%US$235.75+0.44%
iShares Biotechnology ETFIBB2035.1萬0.19%108.2億 USD0.44%US$200.84-1.67%
iShares Russell Mid-Cap Growth ETFIWP1339.19萬0.07%200.95億 USD0.23%US$140.34-0.46%
iShares Russell Mid-Cap ETFIWR985.23萬0.02%567.65億 USD0.18%US$109.61+0.12%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
